Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment With Long Acting GnRH Antagonist Degarelix in Women With Endometriosis Recurrence

Trial Profile

Treatment With Long Acting GnRH Antagonist Degarelix in Women With Endometriosis Recurrence

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Degarelix (Primary) ; Goserelin
  • Indications Endometriosis
  • Focus Therapeutic Use

Most Recent Events

  • 25 Apr 2016 Status changed from recruiting to completed.
  • 02 Dec 2013 Planned end date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
  • 29 Nov 2012 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top